Related Experiment Video

Updated: May 5, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

14.0K

Developing oncology biosimilars: an essential approach for the future

Jame Abraham1

  • 1Director of Breast Oncology Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

Seminars in Oncology
|November 26, 2013
PubMed

Insights

Biosimilars offer a promising avenue to increase patient access to vital biologic therapies, particularly in oncology. These advanced biologic drugs are designed to be highly similar to existing treatments, aiming to reduce healthcare costs.

Area of Science:

  • Biotechnology
  • Oncology
  • Pharmaceutical Sciences

Background:

  • Biologic therapies have transformed disease treatment, especially cancer, and are standard in oncology guidelines.
  • Biologics are complex, large-molecule proteins manufactured through intricate processes.
  • Patent expirations for key biologics are driving the development of biosimilars.

Purpose of the Study:

  • To discuss the development and implications of biosimilars in oncology.
  • To differentiate biosimilars from generic small-molecule drugs.
  • To highlight the role of biosimilars in improving patient access and reducing healthcare costs.

Main Methods:

  • Review of biologic therapy landscape in oncology.
  • Analysis of biosimilar development principles.
  • Examination of regulatory and economic factors influencing biosimilar adoption.

Main Results:

  • Biosimilars are highly similar, not identical, to reference biologics due to inherent complexity.
  • Biosimilars are distinct from generic drugs, which are identical small molecules.
  • The development of biosimilars is a strategic response to expiring biologic patents.

Conclusions:

  • Biosimilars are crucial for enhancing patient access to advanced cancer therapies.
  • The integration of biosimilars is expected to significantly reduce healthcare expenditures.
  • Understanding the unique nature of biosimilars is key for their successful clinical implementation.

More Related Videos

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

7.3K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

12.8K

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
370
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K